Ramsay Health Care suspends dividend and raises capital

Ramsay Health Care Limited (ASX: RHC) shares are in a trading halt after the company announced a capital raising.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Australia's largest hospital operator Ramsay Health Care Limited (ASX: RHC) were placed in a trading halt earlier today, pending details of a capital raising.

a woman

Capital raising and dividend suspension

Ramsay is looking to undertake an equity raising worth up to $1.4 billion, consisting of $1.2 billion in an underwritten institutional placement of shares and $200 million in a non-underwritten share purchase plan.

The institutional placement will be conducted at $56.00, representing a 12.9% discount from Ramsay's last closing price of $64.29 and will see approximately 21.4 million new shares being issued. Following the completion of the placement, Ramsay will be looking to raise up to $200 million from retail shareholders through a share purchase plan.

In addition to the capital raising, Ramsay announced that due to the impact of the coronavirus pandemic on cash flow, the company has temporarily suspended payment of its ordinary share dividends. However, Ramsay did note that it will continue to pay dividends on its Convertible Adjustable Rate Equity Securities (CARES).

Why is Ramsay raising capital?

In an announcement to the market this morning, Ramsay cited that the suspension of elective procedures due to COVID-19 has led to an uncertain operating environment. As a result, the equity raising will provide Ramsay with financial flexibility and security in the current environment, whilst also allowing the company to take advantage of any future growth opportunities.

Ramsay has operations in more than 500 locations across 11 countries. As a result of the coronavirus pandemic, respective governments in each of Ramsay's major operating regions deferred elective procedures in private hospitals in order to support public health systems.

Last month, Ramsay withdrew its earnings guidance for FY20, citing the uncertain duration and impact of the coronavirus pandemic. With elective surgeries being the main source of revenue for private operators like Ramsay, the Australian government recently provided private hospitals with a $1.3 billion viability guarantee. However, with some elective surgeries being resumed, the income that private hospitals receive will reduce the funding flow from the government.

Should you buy?

Restrictions on elective and non-urgent surgeries will be partially lifted by the federal government on 27 April. As a result, post-cancer, hip, knee, and other joint replacement surgeries will be able to go ahead in addition to IVF procedures.

The Ramsay share price has tanked more than 20% from its high in mid-February of $80.93. Ramsay shares will remain in a trading halt until the commencement of normal trading on Thursday, 24 April 2020.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor analysing x-rays.
Healthcare Shares

4DMedical shares are rocketing 11% today. Is a short squeeze starting?

Short sellers may be feeling the heat after this week’s rally.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Shares surge as ASX biotech charts road to redemption

A recent major setback might not be so bad.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Forget CSL shares, I'd buy this ASX biotech stock instead

Brokers tip this other ASX biotech stock to climb up to 76% higher.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

CSL acknowledges "disappointing" results but aims to do better

The search for a new CEO also goes on.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

This sector is coming back into favour.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown

4DMedical and Telix are both Aussie health innovators—here’s which ASX share gets my vote in this biotech battle.

Read more »

cochlear happy, share price rise, up, increase
Healthcare Shares

Cochlear share price rebounds 53% from 10-year low: Can it keep climbing?

The shares are still down 47% for the year to date.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Two broker upgrades put CSL shares back in focus

CSL is back on the radar after two broker upgrades.

Read more »